Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080193 | 1.00 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL2825299 | 0.98 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL13687323 | 0.88 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL3399852 | 0.81 | CHRM5 (0.57) | MAPTALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL24003473 | 0.80 | KDM4E (0.52) | MAPTALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL20881929 | 0.80 | HSD17B10 (0.47) | MAPTALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL3669194 | 0.78 | CHRM5 (0.59) | MAPTALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4410668 | 0.78 | MAPT (1.00) | MAPTALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL481833 | 0.78 | SMN1; SMN2 (0.66) | ALDH1A1SMN1; SMN2KDM4EUSP2 | |
| SCHEMBL8613123 | 0.78 | SIGMAR1 (0.51) | MAPTALDH1A1SMN1; SMN2GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108329232-B | Hydrazide derivative and application thereof | 浙江大学 | 2021-04-16 | — | — | CN | disclosed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-3215505-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| CN-107108638-A | Piperidyl PyrazolopyrimidinonecGMP and application thereof | 拜耳制药股份公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| US-20150031665-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-20140315876-A1 | BETA-LACTAMASE INHIBITORS | CUBIST PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20020010174-A1 | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | US | disclosed |
| WO-2001090083-A1 | 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001029021-A1 | NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029050-A2 | CONDENSED PYRROLE DERIVATIVES AS NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028979-A2 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029020-A2 | NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028981-A1 | 1-CYCLOHEXENE-1-CARBOXYLIC ACID AND 1-CYCLOHEXENE-1-CARBOXYLATES AS NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028996-A2 | PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031665-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | MAPT 3656/4885ALDH1A1 167/4885SMN1; SMN2 2925/4885 |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, BBOX1 | MAPT 3716/4885ALDH1A1 158/4885SMN1; SMN2 2946/4885 |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | HAMP, SERPINC1, PRSS8 | MAPT 4541/4885ALDH1A1 404/4885SMN1; SMN2 3486/4885 |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | HAMP, SERPINC1, PRSS8 | MAPT 4541/4885ALDH1A1 404/4885SMN1; SMN2 3486/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPT 1000/4885ALDH1A1 2864/4885SMN1; SMN2 4475/4885 |
| US-20140315876-A1 | BETA-LACTAMASE INHIBITORS | LCT, BCHE, GANAB | MAPT 3210/4885ALDH1A1 842/4885SMN1; SMN2 2833/4885 |
| US-20020010174-A1 | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation | BDKRB2, NPSR1, BDKRB1 | MAPT 4885/4885ALDH1A1 1088/4885SMN1; SMN2 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.